PTGS2 and hyperlipidemia: Similarly, PTGS2(prostaglandin-endoperoxide synthase 2) and CYP19A1(cytochrome P450 family 19 subfamily A member 1) are also predicted to be pivotal target for reducing or reversing hyperlipidemia and obesity [68, 71, 72].